OpGen (NASDAQ:OPGN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of OpGen (NASDAQ:OPGN) in a research note issued to investors on Saturday. The brokerage issued a sell rating on the medical research company’s stock.

OpGen Price Performance

Shares of NASDAQ OPGN opened at $2.20 on Friday. OpGen has a 52-week low of $1.75 and a 52-week high of $38.40. The business’s 50 day moving average is $2.43 and its two-hundred day moving average is $3.78.

OpGen (NASDAQ:OPGN) last posted its quarterly earnings data on Monday, August 19th. The medical research company reported ($1.18) earnings per share for the quarter. OpGen had a negative return on equity of 1,827.76% and a negative net margin of 1,140.36%. The company had revenue of $0.03 million for the quarter.

Hedge Funds Weigh In On OpGen

An institutional investor recently bought a new position in OpGen stock. Chase Investment Counsel Corp acquired a new stake in OpGen, Inc. (NASDAQ:OPGN) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned approximately 2.63% of OpGen at the end of the most recent reporting period. Institutional investors own 2.68% of the company’s stock.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.